GlassScriptPhysician profile
Sue S Chang
NPI 1528054848
$8,926.75
in general payments reported to CMS, 2019-2025
33 companies · $2,039 in 2025
The $2,039 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,130 · 2020: $271 · 2021: $979 · 2022: $1,321 · 2023: $1,208 · 2024: $1,979 · 2025: $2,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,843 · Travel and Lodging: $350 · Education: $32.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,842.64 |
| Travel and Lodging | $350.34 |
| Education | $32.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,050.16 | 2023-2025 | Creon |
| Astrazeneca Pharmaceuticals LP | $1,018.55 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $843.22 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $777.62 | 2019-2024 | Veltassa |
| Akebia Therapeutics INC | $426.98 | 2019-2025 | Vafseo, Auryxia |
| Gilead Sciences, INC. | $413.75 | 2022-2025 | Epclusa |
| Madrigal Pharmaceuticals | $411.89 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $380.05 | 2022-2025 | Acthar |
| Travere Therapeutics, INC. | $326.83 | 2022-2025 | Filspari |
| Glaxosmithkline, LLC. | $302.02 | 2020-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $286.80 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $285.53 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $260.67 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $246.51 | 2021-2025 | |
| Ardelyx, INC. | $211.57 | 2023-2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.37 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.44 | 2023-2025 | Jardiance |
| Genzyme Corporation | $162.71 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $141.82 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $132.63 | 2022-2025 | Tarpeyo |
| Phathom Pharmaceuticals, INC. | $124.80 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $105.39 | 2021-2025 | Keveyis |
| Alexion Pharmaceuticals, INC. | $99.61 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $79.28 | 2023-2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $76.16 | 2021-2024 | Givlaari |
| Opko Pharmaceuticals, LLC | $68.80 | 2019-2021 | |
| Kyowa Kirin, INC. | $60.28 | 2023-2025 | Crysvita |
| Genentech USA, INC. | $57.62 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $53.61 | 2021 | |
| Lilly USA, LLC | $52.59 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $31.27 | 2019 | |
| Horizon Therapeutics Plc | $18.88 | 2022 | |
| Bard Peripheral Vascular, INC. | $17.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.